Complete response for Valeant's ezogabine

FDA issued a complete response letter to Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX) for an NDA for ezogabine as an adjunctive treatment for partial-onset seizures. According to Valeant and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), FDA cited non-clinical reasons for the letter. The partners plan to respond as soon as possible in 2011. ...